4//SEC Filing
Lenz Robert A. 4
Accession 0001610717-25-000028
CIK 0001885522other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:12 PM ET
Size
5.4 KB
Accession
0001610717-25-000028
Insider Transaction Report
Form 4
Lenz Robert A.
Head of R&D
Transactions
- Sale
Common Stock
2025-02-18$1.67/sh−5,614$9,383→ 309,092 total
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
- [F2]This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Neumora Therapeutics, Inc.
CIK 0001885522
Entity typeother
Related Parties
1- filerCIK 0001992908
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 5:12 PM ET
- Size
- 5.4 KB